Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HR17031 Injection in Subjects With Renal Insufficiency
NCT05292495Phase 1Completed
- Sponsor
- Hengrui
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (5 cohorts), sponsored by Hengrui. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Oct 2022; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05292495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292495.